Gastroenterological cancer stands as one of the leading causes of cancer-related deaths worldwide. Remarkable progress has been made in resolving early-stage malignancies; however, the management of intermediate-advanced cancers remains challenging, necessitating a multidisciplinary approach integrating diverse therapeutic strategies.
Recent years have witnessed a paradigm shift in cancer treatment, marked by a transition towards targeted therapies. Unlike traditional chemotherapy, which broadly affects both healthy and cancerous cells, targeted therapies home in on specific proteins critical to cancer development. These therapies, tailored to the unique molecular characteristics of specific cancers, hold great promise for enhanced effectiveness. The latest breakthroughs allow for the customization of treatments based on an individual's tumor profile. Primary types of targeted cancer therapies encompass monoclonal antibodies, small molecule inhibitors, and immunotoxins. The future of intermediate-advanced cancer treatment is poised for transformation, featuring personalized therapies tailored to the genomic profiles of cancer, the precise prediction of treatment outcomes through the analysis of gene mutations, and the early detection of metastasis or recurrence using liquid biopsies.
This Research Topic aims to gather and synthesize innovative strategies for improving the prognosis of intermediate-advanced gastroenterological cancers, encompassing malignancies of the esophagus, stomach, and colon. We would like to provide more evidence for novel therapeutic targets or treatment strategies in the research phases.
We invite submissions of Original Research and Review articles. Case reports demonstrating significant relevance to the treatment of gastroenterological cancers will also be considered. Topics of interest include, but are not limited to:
- The integration of diverse therapeutic strategies for intermediate-advanced gastroenterological cancers
- The utilization of biomaterials-based nanoparticles in cancer treatment
- The development of serum or imaging biomarkers for predicting treatment responses
- Novel or potential therapeutic targets
- Early detection methods for tumor metastasis or recurrence
Gastroenterological cancer stands as one of the leading causes of cancer-related deaths worldwide. Remarkable progress has been made in resolving early-stage malignancies; however, the management of intermediate-advanced cancers remains challenging, necessitating a multidisciplinary approach integrating diverse therapeutic strategies.
Recent years have witnessed a paradigm shift in cancer treatment, marked by a transition towards targeted therapies. Unlike traditional chemotherapy, which broadly affects both healthy and cancerous cells, targeted therapies home in on specific proteins critical to cancer development. These therapies, tailored to the unique molecular characteristics of specific cancers, hold great promise for enhanced effectiveness. The latest breakthroughs allow for the customization of treatments based on an individual's tumor profile. Primary types of targeted cancer therapies encompass monoclonal antibodies, small molecule inhibitors, and immunotoxins. The future of intermediate-advanced cancer treatment is poised for transformation, featuring personalized therapies tailored to the genomic profiles of cancer, the precise prediction of treatment outcomes through the analysis of gene mutations, and the early detection of metastasis or recurrence using liquid biopsies.
This Research Topic aims to gather and synthesize innovative strategies for improving the prognosis of intermediate-advanced gastroenterological cancers, encompassing malignancies of the esophagus, stomach, and colon. We would like to provide more evidence for novel therapeutic targets or treatment strategies in the research phases.
We invite submissions of Original Research and Review articles. Case reports demonstrating significant relevance to the treatment of gastroenterological cancers will also be considered. Topics of interest include, but are not limited to:
- The integration of diverse therapeutic strategies for intermediate-advanced gastroenterological cancers
- The utilization of biomaterials-based nanoparticles in cancer treatment
- The development of serum or imaging biomarkers for predicting treatment responses
- Novel or potential therapeutic targets
- Early detection methods for tumor metastasis or recurrence